Tetrasilver Tetroxide (TSTO)

This source is a short promotional page from the source archive advertising tetrasilver tetroxide (TSTO) — a silver–oxygen compound with the formula Ag₄O₄, also written Ag₂O·Ag₂O₃ and known as silver(I,III) oxide. The page markets the material as an "electron jumping compound" and "molecular battery," pairs a product listing with a set of quoted patent excerpts attributed to the inventor Marvin S. Antelman, and closes with a toxicity summary and a disclaimer.

The document is best read as a sales page and patent-quote digest, not a study. It contains no experimental protocol, no independent replication, no peer-reviewed citation, and no data tables beyond the quoted patent language. Every efficacy claim below is an attributed claim from the page or from the patents it quotes; none is independently verified here. The page itself carries the label "Technical Grade — Not For Human Use."

What the page offers

The listing advertises TSTO in three quantities:

The purchase includes a "TSTO Database" on a USB flash drive, shipped by USPS Priority Mail, "AVAILABLE IN THE USA ONLY." A disclaimer at the bottom repeats that the product is "for Experimental Purposes ONLY," that the site does not give medical advice, and that statements "may not have been evaluated by the FDA."

This framing matters: the vendor simultaneously markets the material as a medicine-adjacent technology (quoting AIDS and skin-disease patents) and disclaims medical use. The medical claims should be treated as patent assertions reproduced for sale, not as clinical findings.

The claimed mechanism: "electron jumping compounds"

The page's central technical claim is that TSTO crystals act as "molecular batteries" or "electron jumping compounds" (EJC). The stated mechanism is a reduction/oxidation (redox) process in which the compound releases electrons, and that this electron release "electrocutes pathogens."

Two quantitative claims appear:

• The page header states the compound "releases ~10 kv of electrical energy through a reduction/oxidation process," with a "Power Flux = 4.0 volts EMF generated per molecule × Concentration (ppm) × 5."
• The patent excerpts state the crystals "release electrons equivalent to 6.4 × 10⁻¹⁹ watts per molecule."

The patent text walks through a per-molecule calculation: each molecule releases two electrons, each with a charge of 1.6 × 10⁻¹⁹ coulombs; the EMF for oxidation of Ag(I) to Ag(II) is given as ~1.98 V (≈2.0 V), citing Antelman's own Encyclopedia of Chemical Electrode Potentials (Plenum, 1982, p. 88). Using P = EI, the per-electron power is computed as 2.0 × 1.6 × 10⁻¹⁹ = 3.2 × 10⁻¹⁹ watts, doubled to 6.4 × 10⁻¹⁹ watts per molecule for two electrons.

The arithmetic is internally consistent as a per-molecule power estimate, but the page's headline "~10 kv" figure is not derived anywhere in the excerpt and is not reconciled with the per-molecule wattage. The "Power Flux = 4.0 volts × ppm × 5" formula is stated without units, derivation, or source. These unsupported quantitative flourishes should not be read as measured outputs.

A key stated condition: the crystals "will not do so unless activated by an oxidizing agent such as Oxone or hydrogen peroxide." In other words, the page itself says TSTO is not self-activating — it requires a co-reactant. The page claims "no other drug or anti-microbial functions with the unique method of action of TSTO — it is a new class of medicine," and adds that it "does not stain organic matter," is "light stable," and "must be syringe-filtered for injection."

Reported antimicrobial concentrations

The page lists "power flux to effectuate 100% kills" for several organisms. The formatting in the source is garbled, but the recoverable pairing appears to be:

The layout is ambiguous and the mapping of numbers to organisms is not reliable from this page alone. The patent excerpts supply cleaner figures, quoted below.

Patent excerpts reproduced on the page

The page quotes a series of Antelman patents. These are patent claims and specifications, which describe intended function and asserted results; they are not peer-reviewed evidence of efficacy. See Patent as Evidence for the general evidentiary problem.

• US5336499 / US5571520 — "Molecular Crystal Device for Pharmaceuticals." Claims that activated crystals "release electrons equivalent to 6.4 × 10⁻¹⁹ watts per molecule which in effect electrocute pathogens." States effectiveness "at such low concentrations as 0.3 PPM" as preservatives in cosmetics and pharmaceuticals, and as active ingredients against Staphylococcus aureus and epidermidis — the latter "completely destroys" in a nutrient broth culture of about 1 million organisms at 0.6 PPM — Candida albicans (spelled "albercans" in the source) at 2.5 PPM, and "the AIDS virus at 18 PPM."

• US5223149 — "Trivalent Silver Water Treatment Compositions." States the trivalent silver complexes were evaluated against gram-positive and gram-negative bacteria and algae "in accordance with the EPA protocols for swimming pools, which require 100% kills of bacteria within ten minutes." Claims the compounds "far exceeded the bacteria requirements at concentrations of one PPM or less of silver," and were effective with and without persulfate salts at 10 PPM.

• US5211855 — "Method of Treating Water Employing Tetrasilver Tetroxide Crystals." Repeats the 6.4 × 10⁻¹⁹ watts/molecule figure and claims that at 0.3 PPM the activated crystals "kill 100% of 100 K/cc Streptococcus faecalis, and E. coli colonies in three minutes," meeting the ten-minute EPA criterion for swimming pools and hot tubs.

• US6258385 — "Tetrasilver Tetroxide Treatment for Skin Conditions." Claims treatment and cure of dermatological conditions "ranging from dermatitis, acne and psoriasis to herpes and skin ulcers."

• US5073382 — "Divalent Silver Alkaline Bactericide Compositions." Claims "100% kills upon cultures of anaerobic bacteria colonies of 100K/cc within 5 minutes."

• US5098582 — "Divalent Silver Oxide Bactericides." Claims conformance to EPA requirements of 100% kills of 100K/cc Streptococcus faecalis within 10 minutes, usability in high-salt water "without halide curdy precipitate formation," and no skin staining.

• US2006105057 / US2004022868 — "Compositions using tetrasilver tetroxide and methods for management of skin conditions." Lists a broad range of conditions claimed to be preventable, treatable, or manageable: eczema, psoriasis, dermatitis, disease-induced skin ulcers, "undefined tropical diseases," shingles, rashes, bedsores, cold sores, blisters, boils, herpes simplex, acne, pimples, skin chafing, cracking, itchiness, peeling, and warts.

• US5017295 — "Divalent Silver Bactericide for Water Treatment." Claims advantages over chlorination (odorless, non-volatile) and over monovalent silver compounds (which "do not decompose in the presence of light and resist precipitation by halides" — the sentence as quoted is internally confusing).

• US5676977 — "Method of Curing AIDS with Tetrasilver Tetroxide Molecular Crystal Devices." Claims "a single intravenous injection of the devices is all that is required for efficacy at levels of about 40 PPM of human blood."

• WO9745133 — "Use of Tetrasilver Tetroxide Molecular Crystals in the Preparation of a Medicament for Treatment of AIDS." Repeats the single-injection / ~40 PPM claim.

The page also links to the Wikipedia article on silver(I,III) oxide, and to a larger "Antelman, Martin: TetraSilver TetrOxide Articles & Patents Database" hosted on the same site.

Toxicity summary quoted on the page

The page reproduces a short acute-toxicity profile:

These are the only quantitative safety figures on the page. No test species, laboratory, method, or date is given, so the provenance of these LD₅₀ values cannot be assessed from this source.

Limitations and open questions

• No primary data. The page is a sales listing plus patent quotations. It reports no experiments performed by the page's author, no controls, and no independent replication.
• Patents are not proof of efficacy. A granted patent asserts novelty and utility; it does not establish that the claimed effect occurs in practice. The AIDS-cure and skin-disease claims in particular rest entirely on patent language.
• Mechanism is asserted, not demonstrated. The "electron jumping" / "molecular battery" model is a proposed explanation. The page's own statement that activation by an oxidizer is required is a significant caveat that complicates the "self-contained molecular battery" framing.
• Internal inconsistencies. The "~10 kv" headline, the "4.0 volts × ppm × 5" formula, and the 6.4 × 10⁻¹⁹ watts/molecule figure are not reconciled. The organism/concentration table is garbled.
• Regulatory status. The page itself notes the statements "may not have been evaluated by the FDA" and labels the product "Not For Human Use." The intravenous-injection claims in the patents are not accompanied by any clinical trial data on this page.
• Open questions. What independent microbiological testing, if any, exists for TSTO? What is the actual chemical fate of Ag(I,III) oxide in aqueous or biological media? Are the quoted LD₅₀ values traceable to a named study? These cannot be answered from this source.

Relationship to existing wiki content

This dossier sits alongside the other the source archive patent-and-press dossiers already in the wiki (the E-Cat, Bedini, and BSCT entries), which share the same evidentiary pattern: patent claims and vendor assertions presented without independent verification. It strengthens the wiki's existing treatment of Patent as Evidence and feeds the comparison page Tetrasilver Tetroxide: The Electron-Jumping Claim, the Patent Set and the Bounded Evidence.